Presenters at ASCO

NewYork-Presbyterian at ASCO 2016

Melissa Accordino, MD

NewYork-Presbyterian & Columbia University Medical Center


Saturday, June 4 @ 8:40-9:00 AM | Using Social Media, Wearables, and Electronic Medical Records to Improve Quality of Cancer Care

Using Technology to Improve Quality and Safety

Trisha Ali-Shaw, MS

NewYork-Presbyterian & Columbia University Medical Center


Monday, June 6 @ 8:00-11:30 AM | Cancer Prevention, Genetics, and Epidemiology

Evaluating genetic and genomic sequencing knowledge from parents and young adult cancer survivors.

Jennifer Amengual, MD

NewYork-Presbyterian & Columbia University Medical Center


Sunday, June 5 @ 8:00-11:30 AM | Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Development of Novel Backbones for the Treatment of Peripheral T-cell Lymphoma (PTCL): The Pralatrexate - Romidepsin Doublet

Alan Astrow, MD (Methodist)

NewYork-Presbyterian & Weill Cornell Medicine


Sunday, June 5 @ 9:24-9:36 AM | Patient and Survivor Care

Just what are spiritual needs of cancer patients? An empirical study in a diverse population

Karla V. Ballman

NewYork-Presbyterian & Weill Cornell Medicine


Friday, June 3 @ 1:20-1:40 PM | Grant Writing Workshop

Working With a Biostatistician

Saturday, June 4 @ 1:00-4:30 PM | Central Nervous System Tumors

Validating RNAseq-signatures of vorinostat (VOR) sensitivity and resistance in patients with newly diagnosed glioblastoma (GBM) treated with VOR, temozolomide and radiation therapy in Alliance N0874/ABTC-0902.

Saturday, June 4 @ 1:15-4:15 PM | Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy

Ten-year survival results of ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1-2 N0 M0 breast cancer who have a positive sentinel node (Alliance).

Monday, June 6 @ 1:00-4:30 PM | Patient and Survivor Care

Identifying risk factors for toxicity in patients (Pts) with hormone-receptor positive (HR+) advanced breast cancer treated with bevacizumab plus letrozole: A CALGB 40503 (Alliance) correlative study.

Yuhua Bao, PhD

NewYork-Presbyterian & Weill Cornell Medicine


Saturday, June 4 @ 1:00-4:30 PM | Health Services Research and Quality of Care

Chemotherapy, acute health care events, and hospice use among stage IV pancreatic cancer patients.

Himisha Beltran, MD

NewYork-Presbyterian & Weill Cornell Medicine


Saturday, June 4 @ 8:00-8:15 AM | Precision Medicine in Advanced Prostate Cancer: Understanding Genomics, Androgen Receptor Splice Variants, and Imaging Biomarkers

"Translating Genomics Into the Clinic"

Saturday, June 4 @ 4:45-6:00 PM | Genitourinary (Prostate) Cancer

Clinical and genomic characterization of metastatic small cell/neuroendocrine prostate cancer (SCNC) and intermediate atypical prostate cancer (IAC): Results from the SU2C/PCF/AACRWest Coast Prostate Cancer Dream Team (WCDT).

Tuesday, June 7 @ 9:45-11:15 AM | Genitourinary (Prostate) Cancer

Inherited mutations in DNA repair genes in men with metastatic castration-resistant prostate cancer

Andrew Brandmaier, MD

NewYork-Presbyterian & Weill Cornell Medicine


Saturday, June 4 @ 8:00-11:30 AM | Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Multimodality therapy in IIIA-N2 NSCLC: Factors associated with treatment selection and survival.

Jonathan Chen, MD, PhD

NewYork-Presbyterian & Weill Cornell Medicine


Sunday, June 5 @ 8:00-11:30 AM | Breast Cancer—HER2/ER

Practice patterns and outcomes for hormone receptor positive and node negative breast cancer patients with intermediate risk Oncotype DX scores: Analysis of the National Cancer Database.

Tessa Cigler, MD

NewYork-Presbyterian & Weill Cornell Medicine


Sunday, June 5 @ 8:00-11:30 AM | Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Suppression of poly-ADP ribose (PAR) levels in PBMCs by veliparib (vel) as a pharmacodynamic (PD) marker associated with survival among women with BRCA1- orBRCA2- (BRCA)-associated metastatic breast cancer (MBC).

Monday, June 6 @ 4:45-6:00 PM | Patient and Survivor Care

Co-Authors

NewYork-Presbyterian & Weill Cornell Medicine


Saturday, June 4 @ 3:00-6:00 PM | Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML.

Saturday, June 4 @ 3:00-6:00 PM | Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Phase Ib/2 study of venetoclax with low-dose cytarabine in treatment-naive patients age ≥ 65 with acute myelogenous leukemia.

Sunday, June 5 @ 8:00-11:30 AM | Breast Cancer—HER2/ER

Practice patterns and outcomes for hormone receptor positive and node negative breast cancer patients with intermediate risk Oncotype DX scores: Analysis of the National Cancer Database.

Sunday, June 5 @ 9:45 AM-12:45 PM | Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

A phase 2 trial of ABVD followed by brentuximab vedotin consolidation in limited stage non-bulky Hodgkin lymphoma.

Sunday, June 5 @ 4:45-6:00 PM | Developmental Therapeutics—Immunotherapy

A first-in-human study of REGN2810, a monoclonal, fully human antibody to programmed death-1 (PD-1), in combination with immunomodulators including hypofractionated radiotherapy (hfRT).

Monday, June 6 @ 8:00-11:30 AM | Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

A phase 2 study of azacitidine (5-AZA) with or without birinapant in subjects with higher risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML).

Monday, June 6 @ 8:00-11:30 AM | Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

A phase 3, open-label, randomized study of the FLT3 inhibitor gilteritinib versus salvage chemotherapy in adults with first relapse or primary refractory FLT3 mutation-positive acute myeloid leukemia.

Monday, June 6 @ 8:00-11:30 AM | Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

INSPIRE: A randomized phase III trial of intravenous rigosertib in patients with higher-risk myelodysplastic syndromes (HR-MDS) after failure of hypomethylating agents (HMAs)—Study design informed by subgroup analyses of ONTIME.

Monday, June 6 @ 8:00-11:30 AM | Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Long-term outcomes of ruxolitinib (RUX) therapy in patients (pts) with myelofibrosis (MF): 5-year update from COMFORT-I.

Monday, June 6 @ 8:00-11:30 AM | Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Outcomes of patients with relapsed and refractory chronic lymphocytic leukemia (CLL) who discontinue idelalisib treatment.

Monday, June 6 @ 8:00-11:30 AM | Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Venetoclax activity in CLL patients who have relapsed after or are refractory to ibrutinib or idelalisib.

Monday, June 6 @ 1:00-4:30 PM | Patient and Survivor Care

Predictors of unplanned hospitalizations among older adults receiving cancer chemotherapy.

Monday, June 6 @ 1:15-2:45 PM | Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Acalabrutinib, a second-generation bruton tyrosine kinase (Btk) inhibitor, in previously untreated chronic lymphocytic leukemia (CLL).

Monday, June 6 @ 1:15-2:45 PM | Raising the Bar for Targeted Therapies for Lung Cancers

Therapy of metastatic, non-small cell lung cancer (mNSCLC) with the anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132).

Simon Mentis Cohen

NewYork-Presbyterian & Weill Cornell Medicine


Saturday, June 4 @ 1:00-4:30 PM | Health Services Research and Quality of Care

The messenger matters: Relative influence of oncologists versus other care team members on advanced cancer patients’ illness understanding.

Scott Ely, MD, MPH

NewYork-Presbyterian & Weill Cornell Medicine


Monday, June 6 @ 8:00-11:30 AM | Hematologic Malignancies—Plasma Cell Dyscrasia

Plasma cell proliferation by SynKii multiplex immunohistochemistry (mIHC) for clinical use in multiple myeloma (MM)

Tito A. Fojo, MD, PhD

Tito A. Fojo, MD, PhD

NewYork-Presbyterian & Columbia University Medical Center


Monday, June 6 @ 5:05-5:25 AM

What Is the Minimal Trial Design for Drug Approval in Rare Cancers?

Julia Lynne Glade Bender, MD

NewYork-Presbyterian & Columbia University Medical Center


Monday, June 6 @ 1:15-1:27 PM | Pediatric Oncology

Role of Antiangiogenic Therapies in Pediatric Solid Tumors

Heather Greenlee, MD

NewYork-Presbyterian & Columbia University Medical Center


Sunday, June 5 @ 8:24-8:36 AM | Patient and Survivor Care

Body mass index, lifestyle factors, and taxane-induced neuropathy in women with breast cancer: The Pathways Study

Dawn Hershman, MD

NewYork-Presbyterian & Columbia University Medical Center


Friday, June 3 @ 3:00-3:20 PM | Grant Writing Workshop

Small Group Discussion Table Leader

Saturday, June 4 @ 1:35-1:55 PM | Financial Toxicity: Risks, Outcomes, and Solutions

Medication Compliance and Out of Pocket Costs

Sunday, June 5 @ 8:12-8:24 AM | Patient and Survivor Care

Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants in SWOG clinical trials.

Fabio Massaiti Iwamoto, MD

NewYork-Presbyterian & Columbia University Medical Center


Monday, June 6 @ 3:00-4:30 PM | Radiomics, Immunotherapy, and Value in Glioma

Joseph Jurcic, MD

NewYork-Presbyterian & Columbia University Medical Center


Sunday, June 5 @ 8:30-8:50AM | Highlights of the Day Session I

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Kevin Kalinsky, MD, MS

NewYork-Presbyterian & Columbia University Medical Center


Saturday, June 4 @ 8:00-11:30 AM | Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

(Co-Author) Trop-2 as a therapeutic target for the antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132), in patients (pts) with previously treated metastatic small-cell lung cancer (mSCLC).

Monday, June 6 @ 1:27-1:39 PM | Melanoma/Skin Cancers

A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and vulvovaginal melanomas: A trial of the ECOG-ACRIN Cancer Research Group (E2607).

Jason P Lambden, MSPH

NewYork-Presbyterian & Weill Cornell Medicine


Monday, June 6 @ 1:00-4:30 PM | Patient and Survivor Care

Accuracy of oncologists’ life-expectancy estimates provided to their advanced cancer patients: Correlates and outcomes.

Nicole Lamanna, MD

Nicole Lamanna, MD

NewYork-Presbyterian & Columbia University Medical Center


Monday, June 6 @ 1:15-1:27 PM | Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

PI3 Kinase Inhibition in Chronic Lymphocytic Leukemia

Andrew B. Lassman, MD

NewYork-Presbyterian & Columbia University Medical Center


Saturday, June 4 @ 1:00-4:30 PM

A phase 2 study on efficacy, safety and intratumoral pharmacokinetics of oral selinexor (KPT-330) in patients with recurrent glioblastoma (GBM)

Sunday, June 5 @ 8:00-11:30 AM | Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM)

Sunday, June 5 @ 10:12-10:24 AM | Central Nervous System Tumors

An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG oncology/RTOG 0525 and 0825

John Leonard, MD

NewYork-Presbyterian & Weill Cornell Medicine


Saturday, June 4 @ 1:15-2:30 PM | Differences in Approaches to Hodgkin Lymphoma Across the Adolescent and Young Adult Divide

Point: Adult Approach to Adolescent and Young Adult Hodgkin Lymphoma

Sunday, June 5 @ 8:00-11:30 AM | Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

A phase I, open-label study of GSK2816126, an enhancer of zeste homolog 2 (EZH2) inhibitor, in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (tFL), other non-Hodgkin’s lymphomas (NHL), multiple myeloma (MM) and solid tumor.

Jennifer Levine, MD

NewYork-Presbyterian & Columbia University Medical Center


Friday, June 3 @ 4:12-4:24 PM | Pediatric Oncology I

Nonsurgical premature menopause (NSPM) in the Childhood Cancer Survivor Study (CCSS): Prevalence, risk factors, and reproductive outcomes.

Gulam Abbas Manji, MC, PhD

NewYork-Presbyterian & Columbia University Medical Center


Monday, June 6 @ 8:00-11:30 AM | Sarcoma

Phase 1/2 study of combination therapy with pexidartinib and sirolimus to target tumor-associated macrophages in malignant peripheral nerve sheath tumors.

Justin T. Matulay, MD

NewYork-Presbyterian & Columbia University Medical Center


Monday, June 6 @ 1:00-4:30 PM | Genitourinary (Nonprostate) Cancer

Natural history of clinical complete response to neoadjuvant chemotherapy for urothelial carcinoma of the bladder: Updated single-institution experience.

Ana Molina, MD

NewYork-Presbyterian & Weill Cornell Medicine


Saturday, June 4 @ 1:00-4:30 PM | Genitourinary (Prostate) Cancer

(Co-Author) Exploring the role of RB and AR in a phase II randomized multicenter trial of abiraterone acetate with or without cabazitaxel in metastatic castration resistant prostate cancer (mCRPC).

Babak B. Navi, MD, MS

NewYork-Presbyterian & Weill Cornell Medicine


Monday, June 6 @ 8:00-11:30 AM | Cancer Prevention, Genetics, and Epidemiology

Risk of arterial thromboembolism in patients with colorectal cancer.

Adrienne Phillips, MD

NewYork-Presbyterian & Weill Cornell Medicine


Sunday, June 5 @ 9:57 AM-10:09 PM | Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

A prospective, multicenter, randomized study of anti-CCR4 monoclonal antibody mogamulizumab (moga) vs investigator's choice (IC) in the treatment of patients (pts) with relapsed/refractory (R/R) Adult T-cell Leukemia-Lymphoma (ATL)

Tiffany Pinchinat, MD

NewYork-Presbyterian & Weill Cornell Medicine


Sunday, June 5 @ 8:00-11:00 AM | Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy

The changing utilization of neoadjuvant chemotherapy among different racial groups and its effect on mastectomy rates.

Naiyer Rizvi, MD

NewYork-Presbyterian & Columbia University Medical Center


Saturday, June 4 @ 2:09-2:21 PM | Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Immunotherapy in Rare Thoracic Malignancies

Sunday, June 5 @ 8:00-11:30 AM | Developmental Therapeutics—Immunotherapy

A phase 1 study of enoblituzumab in combination with pembrolizumab in patients with advanced B7-H3-expressing cancers.

Joseph T. Ruggiero, MD

NewYork-Presbyterian & Weill Cornell Medicine


Friday, June 3 @ 1:00-1:20 PM | Maintenance of Certification and Lifelong Learning Workshop

"American Board of Internal Medicine 2015 Update"

Ahmed Sawas, MD

NewYork-Presbyterian & Columbia University Medical Center


Monday, June 6 @ 8:00-11:30 AM | Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

A first in human experience of the anti-CD37 antibody-drug conjugate AGS67E in lymphoid malignancies.

Gary Schwartz, MD

NewYork-Presbyterian & Columbia University Medical Center


Friday, June 3 @ 3:40-3:00 PM | Grant Writing Workshop

Small Group Discussion Table Leader

Sunday, June 5 @ 9:36-9:48 AM | Sarcoma

Tyrosine Kinase Inhibitors in Non-Gist Sarcomas: Are We Making Progress?

Manish Shah, MD

NewYork-Presbyterian & Weill Cornell Medicine


Saturday, June 4 @ 8:00-11:30 AM | Gastrointestinal (Noncolorectal) Cancer

Results of a phase I study of GS-5745 in combination with mFOLFOX in patients with advanced unresectable gastric/GE junction tumors

Saturday, June 4 @ 8:00-11:30 AM | Gastrointestinal (Noncolorectal) Cancer

A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of GS-5745 combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma.

Saturday, June 4 @ 8:00-11:30 AM | Gastrointestinal (Noncolorectal) Cancer

Pembrolizumab for previously treated metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: phase 2 KEYNOTE-180 study

Saturday, June 4 @ 8:00-11:30 AM | Gastrointestinal (Noncolorectal) Cancer

KEYNOTE-181: Phase 3, open-label study of second-line pembrolizumab vs single-agent chemotherapy in patients with advanced/metastatic esophageal adenocarcinoma.

Saturday, June 4 @ 8:00-11:30 AM | Gastrointestinal (Noncolorectal) Cancer

The BRIGHTER trial: A phase III randomized double-blind study of BBI-608 + weekly paclitaxel versus placebo (PBO) + weekly paclitaxel in patients (pts) with pretreated advanced gastric and gastro-esophageal junction (GEJ) adenocarcinoma

Saturday, June 4 @ 1:15-2:30 PM

Locally Advanced Esophageal and Gastric Cancers: When Neoadjuvant Therapy Fails

Sunday, June 5 @ 8:00-11:30 AM | Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Phase I study of BPM 31510 in advanced solid tumors: Omics-based molecular correlation to outcome for patient stratification

Scott Tagawa, MD

NewYork-Presbyterian & Weill Cornell Medicine


Saturday, June 4 @ 1:00-4:30 PM | Genitourinary (Prostate) Cancer

Final Results of 2-Dose Fractionation of 177Lu-J591 for Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Sunday, June 5 @ 8:00-11:30 AM | Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Results from a phase 1b/2 study of RX-0201, a novel AKT-1 antisense, combined with everolimus to treat metastatic clear cell renal carcinoma.

Monday, June 6 @ 10:12-10:24 AM | Genitourinary (Prostate) Cancer

TAXYNERGY: Randomized trial of early switch from first-line docetaxel (D) to cabazitaxel (C) or vice versa with circulating tumor cell (CTC) biomarkers in patients (pts) with metastatic castration-resistant prostate cancer